Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05450978 · ClinicalTrials.gov registry record

Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding

A clinical trial of Epilepsy and Pregnancy Related, sponsored by University of Pittsburgh.

Recruiting
Registry status
60
Enrollment target
1
Study location

NCT05450978 is a study of Epilepsy and Pregnancy Related that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 60 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05450978, a study of Epilepsy and Pregnancy Related, is actively recruiting participants, sponsored by University of Pittsburgh.

RECRUITING
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

This project focuses on anti-seizure medication (ASM) clearance and physiological factors determining blood concentrations in pregnant adult women with epilepsy and amounts of exposure to their unborn children and nursing infants.

Interventions

  • DRUG Lamotrigine
  • DRUG Levetiracetam
  • DRUG Oxcarbazepine

Study Locations (1)

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-07-20
Est. Completion 2028-04-01

Sponsor

University of Pittsburgh

1,238 total trials

What the Registry Record Tells You About NCT05450978

The ClinicalTrials.gov registry entry for NCT05450978 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (94% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 3 interventions - of which Lamotrigine is the first listed.

NCT05450978 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05450978 about?

NCT05450978 is a clinical study titled "Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding". This project focuses on anti-seizure medication (ASM) clearance and physiological factors determining blood concentrations in pregnant adult women with epilepsy and amounts of exposure to their unborn children and nursing infants.

What is the current status of trial NCT05450978?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2022-07-20. Estimated completion is 2028-04-01.

What conditions does trial NCT05450978 study?

This clinical trial studies the following conditions: Epilepsy, Pregnancy Related.

What interventions are being tested in trial NCT05450978?

The interventions under investigation include: Lamotrigine (DRUG), Levetiracetam (DRUG), Oxcarbazepine (DRUG).

Who is sponsoring clinical trial NCT05450978?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05450978 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.